In tumors that retain wild-type p53 status (50% of all cancers), its function is usually inactivated by overexpression of endogenous negative regulators, such as murine double minute-2 (MDM2) and MDM4 (also known as MDMX) [3]. Here, TP53 is linked to cancer.